Trial intelligence / Profile preview

Phase I/II study of bevacizumab in metastatic colorectal cancer

jRCT2080220022Phase 2

Sponsor
Chugai Pharmaceutical Co., Ltd.
Start
Sep 2005
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Countries
1
01

Overview

Phase 2 trial of bevacizumab in metastatic colon cancer (mCRC), sponsored by Chugai Pharmaceutical Co., Ltd.

02

Drugs

bevacizumab
03

Conditions

metastatic colon cancer (mCRC)

Beyond the preview

Go deeper on jRCT2080220022.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2080220022.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call